Improved early results for patients with extensively drug-resistant tuberculosis and HIV in South Africa

International Journal of Tuberculosis and Lung Disease

Volumn 13, Issue 7, 2009, Pages 855-861

  O'Donnell, Max R ^a   Padayatchi, N ^b,c   Master, I ^d   Osburn, G ^d   Horsburgh, C R ^a,e  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d King George V Hospital   (South Africa)

^e BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Extensively drug resistant tuberculosis; HIV AIDS; South Africa; Treatment

Indexed keywords

CAPREOMYCIN; EFAVIRENZ; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ADVERSE OUTCOME; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CONTROLLED STUDY; DRUG FATALITY; DRUG SENSITIVITY; DRUG TOLERANCE; ELECTROLYTE DISTURBANCE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SOUTH AFRICA; SPUTUM CULTURE; TREATMENT OUTCOME; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SOUTH AFRICA; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 67651204941     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. World Health Organization. Global tuberculosis control - surveillance, planning, financing. WHO report 2008. WHO/HTM/TB/2008.393. Geneva, Switzerland: WHO, 2008.
2. Dye C, Bassili A, Bierrenbach A L, et al. Measuring tuberculosis burden, trends, and the impact of control programmes. Lancet Infect Dis 2008; 8: 233-243.
3. Chaisson R, Martinson N. Tuberculosis in Africa - combating an HIV-driven crisis. N Engl J Med 2008; 358: 1089-1092.
4. Horsburgh C R Jr. The global problem of multidrug-resistant tuberculosis: the genie is out of the bottle. JAMA 2000; 283: 2575-2576. (Pubitemid 30324202)
5. Raviglione M, Smith I. XDR tuberculosis - implications for global public health. N Engl J Med 2007; 356: 656-659. (Pubitemid 46257227)
6. Gandhi N R, Moll A, Sturm A W, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580. (Pubitemid 44780738)
7. Wells C D, Cegielski J P, Nelson L J, et al. HIV infection and multidrug-resistant tuberculosis-the perfect storm. J Infect Dis 2007; 196 (Suppl): S86-S107. (Pubitemid 47206088)
8. Schluger N W. The impact of drug resistance on the global tuberculosis epidemic. Int J Tuberc L Dis 2000; 4 (Suppl 1): S71-S75.
9. Centers for Disease Control and Prevention (CDC). Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec 2006; 81: 430-432.
10. Andrews J R, Shah N S, Gandhi N, Moll T, Friedland G. Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in South Africa. J Infect Dis 2007; 196 (Suppl): S482-S490.
11. Centers for Disease Control and Prevention (CDC). Extensively drug-resistant tuberculosis - United States, 1993-2006. MMWR 2007; 56: 250-253.
12. Kim H-R, Hwang S S, Kim H J, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 2007; 45: 1290-1295.
13. Migliori G B, Lange C, Girardi E, et al. Extensively drug-resistant tuberculosis is worse than multidrug-resistant tuberculosis: different methodology and settings, same results. Clin Infect Dis 2008; 46: 958-959.
14. Centers for Disease Control and Prevention. Revised definition of extensively drug-resistant tuberculosis. MMWR 2006; 55: 1176.
15. Laserson K F, Thorpe L E, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 640-645. (Pubitemid 40826156)
16. Breen R A, Miller R F, Gorsuch T, et al. Adverse events and treatment interruption in tuberculosis patients with and without HIV coinfection. Thorax 2006; 61: 791-794. (Pubitemid 44369404)
17. Reisner B A, Gatson M A, Wood G L. Evaluation of Mycobacteria Growth Indicator Tubes for susceptibility testing of Mycobacterium tuberculosis to isoniazid and rifampin. Diagn Microbiol Infect Dis 1995; 22: 325-329.
18. Rüsch-Gerdes S, Pfyffer G E, Casal M, Chadwick M, Siddiqi S. Multicentre laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 2006; 44: 688-692.
19. Buthelezi S. Situational analysis of TB drug resistance in KwaZulu-Natal Province, Republic of South Africa. In: Program and abstracts of the 2nd Global XDR-TB Task Force Meeting. Geneva, Switzerland: WHO, 2008.
20. Farmer P, Kim J Y. Community-based approaches to the control of multidrug-resistant tuberculosis: introducing 'DOTS-plus.' BMJ 1998; 317: 671-674.
21. Migliori G B, Ortmann J, Girardi E, et al. Extensively drug-resistant tuberculosis, Italy and Germany. Emerg Infect Dis 2007; 13: 780-781.
22. Migliori G B, Lange C, Centis R, et al. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur Respir J 2008; 31: 1155-1159.
23. Mitnick C, Shin S S, Seung K J, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008; 359; 563-574.
24. Nahid P, Gonzalez L C, Rudoy I, et al. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med 2007; 175: 1199-1206. (Pubitemid 46855463)
25. Montori V M, Kleinbart J, Newman T B, et al. Tips for learners of evidence-based medicine: 2. Measures of precision (confidence intervals). CMAJ 2004; 171: 611-615.
26. Zhou Z, Rahme E, Abrahamowicz M, Pilote L. Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation. Am J Epidemiol 2005; 162: 1016-1023. (Pubitemid 41619473)
27. Akksilp S, Karnkawinpong O, Wattanaamornkiat W, et al. Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand. Emerg Infect Dis 2007; 13: 1001-1007. (Pubitemid 47048071)
28. Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV J Antimicrob Chemother 2006; 58: 1299-1302. (Pubitemid 44884158)
29. Schwander S K, Dietrich M, Mugyenyi P, et al. Clinical course of human immunodeficiency virus type 1 associated pulmonary tuberculosis during short-course antituberculosis therapy. East Afr Med J 1997; 74: 543-548. (Pubitemid 127387178)
30. Sanguanwongse N, Cain K P, Suriya P, et al. Antiretroviral therapy for HIV-infected tuberculosis patients saves lives but needs to be used more frequently in Thailand. J Acquir Immune Defic Syndr 2008; 48: 181-189.
31. Zelnick J, O'Donnell M. The impact of the HIV/AIDS epidemic on hospital nurses in KwaZulu Natal, South Africa: nurses' perspectives and implications for health policy. J Public Health Policy 2005; 26: 163-185. (Pubitemid 40875020)
32. Thomas A, Ramachandran R, Rehaman F, et al. Management of multidrug resistance tuberculosis in the field: tuberculosis research centre experience. Indian J Tuberc 2007; 54: 117-124.
33. Basu S, Andrews J R, Poolman E M, et al. Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. Lancet 2007; 370: 1500-1507. (Pubitemid 47628865)
34. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008.